Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper
Oliver Pfaar, Ioana Agache, Karl‐Christian Bergmann, et al.
Allergy (2020) Vol. 76, Iss. 3, pp. 629-647
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma
Heimo Breiteneder, Yaqi Peng, Ioana Agache, et al.
Allergy (2020) Vol. 75, Iss. 12, pp. 3039-3068
Open Access | Times Cited: 197
Guideline on allergen immunotherapy in IgE-mediated allergic diseases
Oliver Pfaar, Tobias Ankermann, Matthias Augustin, et al.
Allergologie select (2022) Vol. 6, Iss. 01, pp. 167-232
Open Access | Times Cited: 83
COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Oliver Pfaar, Ludger Klimek, Marek Jutel, et al.
Allergy (2020) Vol. 76, Iss. 3, pp. 648-676
Open Access | Times Cited: 108
Hot topics in allergen immunotherapy, 2023: Current status and future perspective
Magdalena Zemelka‐Wiącek, Ioana Agache, Cezmi A. Akdiş, et al.
Allergy (2023) Vol. 79, Iss. 4, pp. 823-842
Open Access | Times Cited: 26
European Headache Federation recommendations for placebo and nocebo terminology
Dimos D. Mitsikostas, Charlotte Blease, Elisa Carlino, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 40
Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report
Oliver Pfaar, Karl‐Christian Bergmann, С. Бонини, et al.
Allergy (2021) Vol. 76, Iss. 12, pp. 3589-3612
Open Access | Times Cited: 33
Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study
Marco Contoli, Celeste Porsbjerg, Sarah Buchs, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 2, pp. 445-452.e4
Open Access | Times Cited: 15
One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future
Oliver Pfaar, Peter S. Creticos, Jörg Kleine‐Tebbe, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 9, Iss. 5, pp. 1791-1803
Closed Access | Times Cited: 31
Pivotal role of the optimal dose in allergen immunotherapy
Pascal Werminghaus, Sven Becker, Ludger Klimek, et al.
Allergo Journal International (2025)
Open Access
Safety, Tolerability and Efficacy of Intradermal DNA Vaccine ASP2390 in Adults Allergic to House Dust Mites: A Phase I Study
T Kayser, Ronald Smulders, Tomohiro Kusawake, et al.
Journal of Allergy and Clinical Immunology Global (2025) Vol. 4, Iss. 2, pp. 100404-100404
Open Access
Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients
Stefanie Hölsken, Frederik Krefting, Senta Mühlhaus, et al.
Psoriasis Targets and Therapy (2025) Vol. Volume 15, pp. 9-22
Open Access
Die pivotale Bedeutung der optimalen Dosis in der Allergen-Immuntherapie
Pascal Werminghaus, Sven Becker, Ludger Klimek, et al.
Allergo Journal (2025) Vol. 34, Iss. 1, pp. 36-41
Closed Access
TAPAS—A Prospective, Multicentre, Long-Term Cohort Study in Children, Adolescents and Adults with Seasonal Allergic Rhinitis—Design and Early Results
Michael Gerstlauer, Julia Hiller, Jennifer Raab, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2609-2609
Open Access
Digitally‐enabled, person‐centred care (PCC) in allergen immunotherapy: An ARIA‐EAACI Position Paper
Oliver Pfaar, Bernardo Sousa‐Pinto, Nikolaos G. Papadopoulos, et al.
Allergy (2024) Vol. 79, Iss. 8, pp. 2037-2050
Open Access | Times Cited: 3
First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients
Karl‐Christian Bergmann, Linda Krause, Julia Hiller, et al.
World Allergy Organization Journal (2020) Vol. 14, Iss. 1, pp. 100494-100494
Open Access | Times Cited: 25
Targeted micronutrition via holo-BLG based on the farm effect in house dust mite allergic rhinoconjunctivitis patients – first evaluation in a standardized allergen exposure chamber
Karl‐Christian Bergmann, Anke Graessel, Jennifer Raab, et al.
Allergo Journal International (2021) Vol. 30, Iss. 4, pp. 141-149
Open Access | Times Cited: 21
Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen
Lars Ahlbeck, Emelie Ahlberg, Janne Björkander, et al.
Clinical & Experimental Allergy (2022) Vol. 52, Iss. 6, pp. 747-759
Open Access | Times Cited: 15
Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model
Bernardo Sousa‐Pinto, Luís Filipe Azevedo, Ana Sá‐Sousa, et al.
Clinical and Translational Allergy (2022) Vol. 12, Iss. 3
Open Access | Times Cited: 14
The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective
Jean Bousquet, Marek Jutel, Oliver Pfaar, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 9, Iss. 5, pp. 1805-1812
Open Access | Times Cited: 16
Subcutaneous allergen immunotherapy in the treatment of allergic respiratory disease
Peter S. Creticos
Allergy and Asthma Proceedings (2022) Vol. 43, Iss. 4, pp. 260-266
Closed Access | Times Cited: 11
111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases
Jan Gutermuth, Martine Grosber, Oliver Pfaar, et al.
Allergologie select (2022) Vol. 6, Iss. 01, pp. 248-258
Open Access | Times Cited: 11
Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans
Alexandra Chabot, Gabriela Senti, Iris Erdmann, et al.
Frontiers in Allergy (2022) Vol. 3
Open Access | Times Cited: 10
Effects of Patients’ Expectation in Dermatology: Evidence from Experimental and Clinical Placebo Studies and Implications for Dermatologic Practice and Research
Wiebke Sondermann, Finja Jockenhöfer, Joachim Dissemond, et al.
Dermatology (2021) Vol. 237, Iss. 6, pp. 857-871
Open Access | Times Cited: 13
Long‐term effects of pollen allergoid tyrosine‐adsorbed subcutaneous immunotherapy on allergic rhinitis and asthma
Christian Vogelberg, Ludger Klimek, Silvia Kruppert, et al.
Clinical & Experimental Allergy (2023) Vol. 54, Iss. 4, pp. 253-264
Open Access | Times Cited: 4
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial
Antje Schuster, Davide Caimmi, Hendrik Nolte, et al.
The Lancet Regional Health - Europe (2024) Vol. 48, pp. 101136-101136
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top